Our study ascertained a clue that rhIL-2 effectively improve the treatment for MDR-TB probably via restoring imbalance of CD4+ T cell activations and favorably modulating Th1/Th17 pathway response in vivo. Here, CD4 is linked to multidrug-resistant tuberculosis.